Thomas Bergh

Director of Finance/CFO at LINC AB

Net worth: 6 M $ as of 31/05/2026

44 year

8 connections

Health Technology

Finance

Consumer Services

Profile

Thomas Bergh is currently a Director at nWise AB, Oncorena Holding AB, Nwise ägare AB, and Animal Probiotics Sweden AB. He is also currently serving as an Investment Manager at MedCap AB (Private Equity) since 2016 and as the Chief Financial Officer at Linc AB since 2020.
Previously, he worked as a Director at Cardiolex Medical AB and Morgan Stanley AB. From 2016 to 2020, he was an Investment Manager at MedCap AB. Mr. Bergh holds a graduate degree and an MBA from Stockholm School of Economics.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
LINC AB 1.38%	31/12/2025	800,000 ( 1.38% )	6 M $	31/05/2026

Thomas Bergh active positions

Companies	Position	Start
LINC AB	Director of Finance/CFO	01/01/2020
MedCap AB (Private Equity) MedCap AB (Private Equity) Investment ManagersFinance MedCap concentrates on investments in the Nordic region as well as in Europe, with a short- or medium-term outlook. The firm targets debt-free SMEs with substantial development potential and valued up to SEK 200 million, or having SEK 50 to 200 million in turnover. They target annual returns on each investment of at least 20 percent. MedCap typically acquires majority stakes in their portfolio companies. They may also take minority stakes, with a minimum of 20 percent. Their portfolio is generally composed of eight to ten firms. They are active investors. They provide experience and access to networks along with expansion capital when necessary. Their targeted investment horizon is five to seven years. MedCap also aims to consolidate the life science market in the Nordic region. To this end, they consider merging ownership to form more robust organizations, as well as collaborating on sales, and product development. They have invested in areas such as technical aids for persons with disabilities, healthcare technologies, systems for vacuum electrodes for ECG, micro-technology and miniaturized separation science, tissue engineering to develop functional substitutes for damaged tissues, and pharmacological solutions for treatment of nicotine addiction.	Private Equity Investor	01/02/2016
nWise AB nWise AB Packaged SoftwareTechnology Services Develops communication apps and provides telecom relay services	Director/Board Member	-
Oncorena Holding AB Oncorena Holding AB Pharmaceuticals: MajorHealth Technology Develops novel pharmacological treatment for metastasing clear cell renal cancer	Director/Board Member	-
Nwise ägare AB	Director/Board Member	-
Animal Probiotics Sweden AB	Director/Board Member	-

All active positions of Thomas Bergh

Former positions of Thomas Bergh

Companies	Position	End
MEDCAP AB	Chief Investment Officer	01/01/2020
Cardiolex Medical AB Cardiolex Medical AB Medical SpecialtiesHealth Technology Develops and markets the vacuum ECG for fixation of ECG electrodes	Director/Board Member	-
Morgan Stanley AB Morgan Stanley AB Investment ManagersFinance Provides wealth management and investment banking services	Corporate Officer/Principal	-

See the detail of Thomas Bergh's experience

Training of Thomas Bergh

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Thomas Bergh's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	10
MedCap AB MedCap AB Medical SpecialtiesHealth Technology Manufactures and sells radiological & ECG equipment, probiotics and nutritional supplements	Health Technology
Stockholm School of Economics Stockholm School of Economics Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Cardiolex Medical AB Cardiolex Medical AB Medical SpecialtiesHealth Technology Develops and markets the vacuum ECG for fixation of ECG electrodes	Health Technology
MedCap AB (Private Equity) MedCap AB (Private Equity) Investment ManagersFinance MedCap concentrates on investments in the Nordic region as well as in Europe, with a short- or medium-term outlook. The firm targets debt-free SMEs with substantial development potential and valued up to SEK 200 million, or having SEK 50 to 200 million in turnover. They target annual returns on each investment of at least 20 percent. MedCap typically acquires majority stakes in their portfolio companies. They may also take minority stakes, with a minimum of 20 percent. Their portfolio is generally composed of eight to ten firms. They are active investors. They provide experience and access to networks along with expansion capital when necessary. Their targeted investment horizon is five to seven years. MedCap also aims to consolidate the life science market in the Nordic region. To this end, they consider merging ownership to form more robust organizations, as well as collaborating on sales, and product development. They have invested in areas such as technical aids for persons with disabilities, healthcare technologies, systems for vacuum electrodes for ECG, micro-technology and miniaturized separation science, tissue engineering to develop functional substitutes for damaged tissues, and pharmacological solutions for treatment of nicotine addiction.	Finance
Morgan Stanley AB Morgan Stanley AB Investment ManagersFinance Provides wealth management and investment banking services	Finance
nWise AB nWise AB Packaged SoftwareTechnology Services Develops communication apps and provides telecom relay services	Technology Services
Oncorena Holding AB Oncorena Holding AB Pharmaceuticals: MajorHealth Technology Develops novel pharmacological treatment for metastasing clear cell renal cancer	Health Technology
Linc AB Linc AB Financial ConglomeratesFinance Invests and develops small and medium-sized product-oriented life science companies	Finance
Nwise ägare AB
Animal Probiotics Sweden AB